New data and partnerships are advancing brain-penetrant enzyme therapy, targeted antibodies, flexible obesity dosing, and frontline lymphoma treatment strategies.
News|Events|January 9, 2025
Advanced Therapies Week 2025: Jan. 20–23, 2025
Author(s)BioPharm International Editors
This event offers knowledge sharing, relationship building, and deal-making for biotech and pharmaceutical companies to advance commercialization of advanced therapies.
Dates: Jan. 20–23, 2025
Location: Kay Bailey Hutchison Convention Center Dallas, Dallas, Texas
Description: This event offers knowledge sharing, relationship building, and deal-making for biotech and pharmaceutical companies to advance commercialization of advanced therapies.
Registration:
Related to this article
Topline phase 3 data show epcoritamab plus R-CHOP reduced the risk of progression or death by 51% in newly diagnosed diffuse large B-cell lymphoma.
Part 2 of the VK2735 maintenance study tests whether daily or weekly oral tablets can hold weight loss first achieved with weekly subcutaneous injections.
CSL and Alentis will co-develop lixudebart, an antibody targeting claudin-1, across 3 rare kidney and liver disease indications.
AL050 aims to treat GBA1-driven Parkinson disease by delivering a GCase enzyme across the blood-brain barrier.
Survodutide advances metabolic disease treatment, while biosimilar capacity expands, FDA delays hemophilia review, and lupus data support next steps.
Litifilimab extended skin responses through 52 weeks in phase 2 AMETHYST data in cutaneous lupus erythematosus, with phase 3 results expected in 2027.
Manufacturing remediation, not efficacy or safety data, is delaying US approval of Novo's h+emophilia A therapy denecimig.